Summary
Health Canada has authorized Svemia, the first generic version of the weight loss drug Wegovy, which is expected to be 45% to 90% cheaper than the brand-name equivalent. This approval marks a major step forward for patient accessibility, with six additional generic semaglutide versions currently under review to further drive down costs.
A cheaper path to a weight loss drug that’s been out of reach for many Canadians may be on the way.
Health Canada authorized the first generic semaglutide injection for weight loss on June 29, 2026. The drug, called Svemia, is a generic version of Wegovy, the brand-name semaglutide injection widely used for chronic weight management, and was developed by Canadian pharmaceutical company Apotex.
What This Approval Actually Means
Generic drugs are required to be pharmaceutically equivalent to their brand-name counterparts. Health Canada’s review confirmed that Svemia meets the same standards for safety, efficacy, and quality required of all generic drugs sold in Canada, meaning it’s expected to work the same way as Wegovy, just at a different price point.
The drug is indicated for once-weekly use in patients aged 12 and over, as a supplement to a reduced-calorie diet and increased physical activity for chronic weight management, the same indication as the brand-name version.
This isn’t Canada’s first brush with generic semaglutide, either. On April 28, 2026, Canada became the first G7 country to approve a generic version of semaglutide at all; that approval was for the diabetes indication. A second generic, also for diabetes, followed on May 1. This latest approval marks the third generic semaglutide product authorized in Canada overall, and the first specifically for weight loss.
Why It Matters: Cost
The headline reason this matters to most Canadians is cost. Generic medications in Canada are typically 45 to 90% cheaper than their brand-name equivalents, according to Health Canada. For a drug class that has drawn criticism for being expensive and often poorly covered by insurance, that price gap could make a meaningful difference for patients who’ve been priced out of treatment.
Health Canada also noted the approval is expected to ease pressure on the broader healthcare system, not just individual patients’ wallets, given how widely semaglutide-based treatments are now prescribed.
More Generics Are Coming
This won’t be the last word on generic semaglutide in Canada. Health Canada is currently reviewing six additional generic semaglutide submissions from other companies, with more regulatory decisions expected in the coming weeks and months. As more generics enter the market, competition is generally expected to drive prices down further.
Health Canada has also noted that its review timelines for generic drug submissions are shorter than many other international regulators, part of why Canada was able to beat other G7 countries to market with a generic version of this drug class.
What Happens Now
As with all approved drugs, Health Canada says it will continue to monitor the safety and effectiveness of generic semaglutide products once they’re on the market, and will act if any safety concerns arise.
For now, the approval is a significant step for Canadians who’ve watched the cost of semaglutide-based weight loss treatment remain a major barrier to access. If you’re currently taking or considering Wegovy for weight management, it’s worth asking your doctor or pharmacist when generic alternatives like Svemia are expected to become available, and what that could mean for your treatment costs going forward.
Subscribe to The Health Insider newsletter where you’ll find many more insights – delivered straight to your inbox.
~ Read more from The Health Insider ~
- The Summer Stomach Bug That’s Causing Misery in the U.S.: What Canadians Need to Know About Cyclospora
Learn about Cyclosporiasis, the parasite causing a distressing outbreak in the U.S.. Discover symptoms, high-risk foods, and how Canadians can stay safe. - Chiropractor or Physiotherapist? Here’s How to Actually DecideStruggling with joint pain, a sports injury, or stiff neck? Learn when to choose a chiropractor versus a physiotherapist for your recovery.
- Your Tears Could Soon Reveal Clues About Your BrainA new stamp-sized graphene sensor can track dopamine levels in tears. Learn how this early-stage tech could revolutionize Parkinson’s screening.
- The 4 Most Trusted Infrared Sauna Brands for Home UseExplore the best low-EMF infrared sauna brands, including Sunlighten, SaunaRay, and more. Compare based on safety, technology, and design.
- Back Pain Is Just a Pain Until One of These 4 Symptoms AppearsMost back pain is harmless. But 4 specific symptoms change everything. Here’s what to watch for and when to go to the ER.
- A Canadian Study Called SHERLOCK Is Testing Whether a Blood Test Can Catch Your Cancer Coming BackA Canadian study is testing whether a blood test can detect cancer’s return months before any scan can. Here’s what it means for survivors.
The information provided on TheHealthInsider.ca is for educational purposes only and does not substitute for professional medical advice. TheHealthInsider.ca advises consulting a medical professional or healthcare provider when seeking medical advice, diagnoses, or treatment. To read about our editorial review process click here.
